Company intelligence / Profile preview

Vandyck

Washington, District of Columbia, United Statesvandyckshop.nl ↗

Ownership: Private
Employees: ~368
Development stage: Commercial

Overview

Vanda has commercialized therapies such as Hetlioz for non‑24‑hour sleep-wake disorder and Fanapt for schizophrenia and bipolar I disorder. Ponvory was recently acquired for multiple sclerosis. The company’s pipeline includes tradipitant (gastroparesis), antisense oligonucleotides for polycythemia vera, and CFTR modulators for cystic fibrosis. Recent clinical setbacks include an FDA rejection of tradipitant in gastroparesis.

Therapeutic areas: GastroenterologyPsychiatryNeurologyHematology
Modalities: Small moleculeAntisense oligonucleotideBiologic
Industry: Biotech

Partnerships

AnaptysBio (imsidolimab development/commercialization contract)Care Capital LLC and Bio*One Capital were founding investors/partners at inception

Beyond the preview

Go deeper on Vandyck.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vandyck.

Explore the full profile